Posted by Michael Wonder on 06 Nov 2019
Bionomics announces fast track designation granted by U.S. FDA to BNC210 development program for the treatment of PTSD
4 November 2019 - Bionomics announced today that the U.S. FDA has granted fast track designation to the BNC210 development program for the treatment of post-traumatic stress disorder and other trauma-related and stressor-related disorders.
Bionomics is currently developing a novel solid dose formulation of BNC210 which has recently been shown to achieve the blood levels predicted as necessary to meet the clinical trial primary endpoint for effectiveness for treating post-traumatic stress disorder (PTSD) patients; preparations are underway for optimisation of the solid dose formulation in anticipation of initiation of a Phase 2b trial in PTSD patients.
